Risk factor reduction in progression of angiographic coronary artery disease

Hoang M. Lai1, Wilbert S. Aronow1, Anthony D. Mercando1, Phoenix Kalen1, Harit V. Desai1, Kaushang Gandhi1, Mala Sharma1, Harshad Amin1, Trung M. Lai1

Abstract

Introduction: To investigate differences between outpatients with progressive and nonprogressive coronary artery disease (CAD) measured by coronary angiography.

Material and methods: Chart reviews were performed in patients in an outpatient cardiology practice having ≥2 coronary angiographies ≥1 year apart. Progressive CAD was defined as 1) new non-obstructive or obstructive CAD in a previously disease-free vessel; or 2) new obstruction in a previously non-obstructive vessel. Coronary risk factors, comorbidities, cardiovascular events, medication use, serum low-density lipoprotein cholesterol (LDL-C), and blood pressure were used for analysis.

Results: The study included 183 patients, mean age 71 years. Mean follow-up duration was 11 years. Mean follow-up between coronary angiographies was 58 months. Of 183 patients, 108 (59%) had progressive CAD, and 75 (41%) had nonprogressive CAD. The use of statins, β-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aspirin was not significantly different in patients with progressive CAD or nonprogressive CAD. Mean arterial pressure was higher in patients with progressive CAD than in patients with nonprogressive CAD (97 ±13 mm Hg vs. 92 ±12 mm Hg) (p < 0.05). Serum LDL-C was insignificantly higher in patients with progressive CAD (94 ±40 mg/dl) than in patients with nonprogressive CAD (81 ±34 mg/dl) (p = 0.09).

Conclusions: Our data suggest that in addition to using appropriate medical therapy, control of blood pressure and serum LDL-C level may reduce progression of CAD.

Key words: coronary artery disease, blood pressure, cholesterol.

Introduction

Progression of coronary artery disease (CAD) diagnosed by coronary angiography is associated with an increase in cardiovascular events [1-3]. The Coronary Artery Surgery Study (CASS) showed that diabetes and elevated serum total cholesterol level were associated with CAD progression [4]. Reduction of elevated serum low-density lipoprotein (LDL) cholesterol by statins reduces progression of CAD diagnosed by coronary angiography [5-7]. Hypertension increases progression of CAD diagnosed by coronary angiography [8, 9]. No significant difference in progression of CAD by
coronary angiography was found in patients treated with the angiotensin-converting enzyme inhibitor perindopril and placebo in the EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) [10].

The primary aim of this study was to investigate differences between patients with progressive and nonprogressive CAD measured by coronary angiography who were followed in an academic cardiology outpatient practice.

Material and methods

Paper and electronic chart reviews were used to screen patients receiving two or more cardiac catheterizations with coronary angiography at least 1 year apart. The date of the first cardiac catheterization with coronary angiography could be any time during follow-up, but could not be any earlier than 3 months before the first visit. The 3-month criterion was chosen because many patients received cardiac catheterization with coronary angiography shortly before starting treatment at our cardiology outpatient practice. Coronary artery disease was diagnosed as previously described [11-19].

Of 1599 patients actively treated in the cardiology practice, 183 patients met the inclusion criteria and were included in the study. Follow-up coronary angiography was performed because of symptoms or an abnormal stress test with myocardial ischemia. The study population was divided into patients with progression of CAD and no progression of CAD. This grouping was based on the two coronary angiographic findings for each patient. Progression of CAD was defined as: 1) new non-obstructive or obstructive CAD in a previously disease-free vessel; or 2) new obstruction in a previously non-obstructive vessel. If a patient had more than two coronary angiographies, comparisons were made between the first coronary angiography and the earliest coronary angiography that followed at least a year later. The coronary arteries analyzed included left main, left anterior descending, left circumflex, and right coronary arteries. Graft and branch vessels were not included in the analysis. The mean duration between the two coronary angiographies was 58 ±41 months.

Patients treated with percutaneous coronary intervention during the first coronary angiography were considered to be completely revascularized. If a new obstructive or non-obstructive lesion developed subsequently, the patient was considered to have progression of CAD. Side branch stenosis was not considered because we could not reliably use side branches to determine progression of CAD and because side branch stenosis does not carry the same prognosis as major branch stenosis.

The reasons for the first coronary angiography were not recorded in the outpatient charts for all patients. The CAD was considered obstructive if the diameter stenosis was ≥ 50% and non-obstructive if the diameter stenosis was < 50%.

For every patient, progress notes of all interim visits, letters of correspondence, medication usage, blood pressure, and laboratory studies including all serum lipid levels from the time of initial presentation to the last follow-up were recorded. Patient co-morbidities were recorded, including CAD, hyperlipidemia, hypertension, diabetes mellitus, cigarette smoking history, congestive heart failure, angina, atrial fibrillation, chronic kidney disease, peripheral arterial disease, abdominal aortic aneurysm, carotid stenosis, transient ischemic attack, and stroke. Dates of the events as well as dates of medication initiation and discontinuation were recorded. Blood pressure was recorded at least once a year, and more frequently if a patient had active management for hypertension.

Statistical analysis

Characteristics between the two groups were then compared and analyzed. Medication use, blood pressure, serum LDL cholesterol levels, other coronary risk factors, and comorbidities at the time of the second coronary angiography were used for analysis.

Data were extracted by the physician authors and tabulated with Microsoft Access 2003 (Microsoft Corporation, Redmond, WA, USA). Data analysis was performed with Microsoft Excel 2003. A p-value of < 0.05 was considered statistically significant.

Student’s t tests were used for continuous variables. \( \chi^2 \) tests were used for dichotomous variables. Logistic regression analysis and Cox regression analysis were also used but were unable to predict progression of CAD because of the similar baseline characteristics and medication use between both groups.

Results

Table I shows the baseline characteristics including age, gender, follow-up time, time between the two coronary angiographies, coronary risk factors, and comorbidities in 108 patients with progression of CAD and in 75 patients with no progression of CAD. Table I also lists levels of statistical significance. The median time between the 2 coronary angiographies were 56 months for the progression of CAD group and 42 months for the group with no progression of CAD. Table II shows the prevalence of use of 23 medications in the patients with and without progression of CAD. There was no significant difference in use of any of these medications between the patients with and without progression of CAD.

Table III shows that patients with progression of CAD had an insignificantly higher systolic blood pressure.
pressure \((p = 0.06)\), a significantly higher diastolic blood pressure \((p = 0.01)\), a significantly higher mean blood pressure \((p = 0.01)\), and an insignificantly higher serum LDL cholesterol \((p = 0.09)\) at the time of the second coronary angiography than the patients with no progression of CAD. The other coronary risk factors listed in Table I did not show a significant difference or borderline significant difference between both groups. Hemoglobin A1c levels were not measured in all diabetics.

Discussion

The CASS Study showed that diabetes and elevated serum total cholesterol level were associated with CAD progression [4]. Reduction of LDL cholesterol by statins reduces progression of CAD diagnosed by coronary angiography [4-7]. Hypertension increases progression of CAD diagnosed by coronary angiography [8, 9]. No significant difference in progression of CAD by coronary angiography was found in patients treated with perindopril vs. placebo in the EUROPA trial [10]. The rate of progression of coronary atherosclerotic plaque diagnosed by intravascular ultrasound was similar in 251 women and in 727 men treated with intensive risk factor modification [20].

In 298 patients in the Emory Angioplasty Versus Surgery trial, native CAD progression was independently correlated with hypertension (odds ratio = 2.4, \(p = 0.03\)) and with percent of small LDL particles (odds ratio = 1.2 for every 5% increase, \(p = 0.01\)) [21]. At 5-year follow-up of 392 patients who underwent coronary artery bypass surgery, percutaneous coronary intervention, or medical therapy, multivariate Cox proportion regression analysis showed that hypertension was a significant independent risk factor for native CAD progression (hazard ratio = 1.3, \(p = 0.048\)) [9].

The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial investigators stated that the extent to which recurrent events in patients with stable CAD is due to progression of a lesion with \(\geq 50\%\) diameter stenosis but not revascularized or < 50% diameter stenosis during optimal medical therapy is unknown [22]. The findings from this study underscore the need for improved therapies to arrest progression of CAD and reliable strategies for selecting stenoses warranting percutaneous coronary intervention [22].

The data from the present study shows that patients with progression of CAD had a significantly higher prevalence of hypertension at baseline \((p = 0.03)\) than the patients with no progression of

### Table I. Baseline characteristics of patients with and without progression of coronary artery disease

| Parameter                                | Progressive coronary artery disease | No progressive coronary artery disease | Value of \(p\)   |
|------------------------------------------|-------------------------------------|----------------------------------------|-----------------|
| Number                                   | 108 (59%)                           | 75 (41%)                               |                 |
| Age [years]                              | 71 ±10                              | 72 ±11                                 | NS              |
| Men                                      | 75 (69%)                            | 56 (75%)                               | NS              |
| Women                                    | 33 (31%)                            | 19 (25%)                               | NS              |
| Follow-up [months]                       | 135 ±59                             | 116 ±59                                | 0.04            |
| Time between two angiographies [months]   | 64 ±43                              | 50 ±37                                 | 0.02            |
| Years of follow-up                       | 1978-2008                           | 1985-2008                              |                 |
| Coronary artery disease                  | 105 (97%)                           | 73 (97%)                               | NS              |
| Hyperlipidemia                           | 104 (96%)                           | 70 (93%)                               | NS              |
| Hypertension                             | 96 (89%)                            | 57 (76%)                               | 0.03            |
| Diabetes mellitus                        | 34 (31%)                            | 24 (32%)                               | NS              |
| Smoker                                   | 53 (49%)                            | 29 (39%)                               | NS              |
| Congestive heart failure                 | 8 (7%)                              | 21 (28%)                               | 0.0006          |
| Angina                                   | 16 (15%)                            | 19 (25%)                               | 0.09            |
| Atrial fibrillation                      | 16 (15%)                            | 14 (19%)                               | NS              |
| Carotid stenosis                         | 6 (6%)                              | 4 (5%)                                 | NS              |
| Stroke                                   | 10 (9%)                             | 5 (7%)                                 | NS              |
| Transient ischemic attack                | 9 (8%)                              | 6 (8%)                                 | NS              |
| Chronic kidney disease                   | 2 (2%)                              | 4 (5%)                                 | NS              |
| Peripheral arterial disease              | 3 (3%)                              | 10 (13%)                               | 0.01            |

NS – not significant
At the time of the second coronary angiography, the patients with progression of CAD had an insignificantly higher systolic blood pressure (p = 0.06), a significantly higher diastolic blood pressure (p = 0.01), a significantly higher mean blood pressure (p = 0.01), and an insignificantly higher serum LDL cholesterol (p = 0.09) than the patients with no progression of CAD. These data are consistent with those previously reported [4-9, 21].

A limitation of this study is that it is a retrospective study. The long time gap between the two coronary angiographies is a strength of this study. However, the longer time may have contributed to the progression of CAD. Another strength of this study is that we knew the dosage of all drugs used, the duration of their administration, and the compliance of medication use as well as the blood pressure and serum lipid levels throughout the study.

On the basis of the previously reported data [5-9, 21] and the data from the present study, patients with CAD should have their blood pressure controlled according to recommended guidelines.

### Table II. Medication use in patients with and without progression of coronary artery disease

| Parameter                          | Progressive coronary artery disease | No progressive coronary artery disease | Value of p |
|------------------------------------|-------------------------------------|---------------------------------------|------------|
| Statins                            | 80 (74%)                            | 55 (73%)                              | NS         |
| Ezetimibe                          | 19 (18%)                            | 9 (12%)                               | NS         |
| Nicotinic acid                     | 1 (1%)                              | 1 (1%)                                | NS         |
| Bile acid sequestrants             | 0 (0%)                              | 0 (0%)                                | NS         |
| Fibrates                           | 4 (4%)                              | 4 (5%)                                | NS         |
| Fish oil                           | 2 (2%)                              | 2 (3%)                                | NS         |
| β-Blockers                         | 85 (79%)                            | 61 (81%)                              | NS         |
| Diuretics                          | 23 (21%)                            | 25 (33%)                              | NS         |
| Angiotensin-converting enzyme inhibitors | 49 (45%)                             | 32 (43%)                              | NS         |
| Angiotensin receptor blockers      | 18 (17%)                            | 18 (24%)                              | NS         |
| Calcium channel blockers           | 43 (40%)                            | 24 (32%)                              | NS         |
| Aspirin                            | 86 (80%)                            | 60 (80%)                              | NS         |
| Ticlopidine                        | 2 (2%)                              | 0 (0%)                                | NS         |
| Clopidogrel                        | 18 (17%)                            | 11 (15%)                              | NS         |
| Aspirin/extended-release dipyridamole | 1 (1%)                             | 1 (1%)                                | NS         |
| Warfarin                           | 10 (9%)                             | 9 (12%)                               | NS         |
| Nitrates                           | 25 (23%)                            | 23 (31%)                              | NS         |
| Digoxin                            | 11 (10%)                            | 5 (7%)                                | NS         |
| Cilostazol                         | 0 (0%)                              | 1 (1%)                                | NS         |
| Insulin                            | 5 (5%)                              | 8 (11%)                               | NS         |
| Thiazolidinediones                 | 8 (7%)                              | 8 (11%)                               | NS         |
| Sulfonylureas                      | 20 (19%)                            | 9 (12%)                               | NS         |
| Metformin                          | 15 (14%)                            | 10 (13%)                              | NS         |

**NS** – not significant

### Table III. Blood pressure and serum low-density lipoprotein cholesterol levels in patients with and without progression of coronary artery disease

| Parameter                      | Progressive coronary artery disease | No progressive coronary artery disease | Value of p |
|-------------------------------|-------------------------------------|---------------------------------------|------------|
| Systolic blood pressure       | 135 ±20                             | 130 ±18                               | 0.06       |
| Diastolic blood pressure      | 77 ±12                              | 73 ±11                                | 0.01       |
| Mean arterial blood pressure  | 97 ±13                              | 92 ±12                                | 0.01       |
| LDL-C level                   | 94 ±40                              | 81 ±34                                | 0.09       |

**LDL-C** – low-density lipoprotein cholesterol
and their serum LDL cholesterol reduced according to recommended guidelines [24].

Acknowledgments

The authors wish to thank the members of Westchester Cardiology Associates in Scarsdale, New York who do not appear in this paper: Stanley Epstein MD, Mitchell Fishbach MD, Gary Gabelman MD, Richard Grose MD, Douglas Hart MD, and Gabriela Grasa MD. Their superb care provided the benefits to their patients cited in this paper.

This study was presented at the American Heart Association Quality of Care and Outcomes Research Annual Scientific Meeting in May, 2011 in Washington, DC.

References

1. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87: 1067-75.
2. Mack WJ, Xiang M, Selzer RH, Hodis HN. Serial quantitative coronary angiography and coronary events. Am Heart J 2000; 139: 993-9.
3. Vigen C, Hodis HN, Selzer RH, et al. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). Am J Cardiol 2005; 95: 1277-82.
4. Alderman EL, Corley SD, Fisher LD, et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol 1993; 22: 1141-54.
5. Daida H, Ouchi Y, Saito Y, et al. Preventing angiographic progression of coronary atherosclerosis with pravastatin. J Atheroscler Thromb 2003; 10: 25-31.
6. Yokoi H, Nobuyoshi M, Mitsudo K, et al. Three-year follow-up results of Angiographic Intervention Trial Using an HMG-CoA Reductase Inhibitor to Evaluate Retardation of Obstructive Multiple Atheroma (ATHEROMA) Study. Circ J 2005; 69: 875-83.
7. Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosvastatin therapy on coronary artery stenoses assed by quantitative coronary angiography. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden. Circulation 2008; 117: 2458-66.
8. Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol 2006; 48: 833-8.
9. Borges JC, Lopes N, Soares PR, et al. Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. J Cardiothorac Surg 2010; 5: 91.
10. Rodriguez-Granillo GA, Vos J, Bruning N, et al. Am J Cardiol 2007; 100: 159-63.
11. Mercando AD, Lai HM, Aronow WS, et al. Reduction in atherosclerotic events through use of aggressive risk factor reduction medications: a retrospective study in an outpatient cardiology practice. Arch Med Sci 2012; 8: 57-62.
12. Lai HM, Aronow WS, Rachdev A, et al. Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration. Arch Med Sci 2008; 4: 140-2.
13. Ramdeen N, Aronow WS, Chugh S, Asija A. Patients undergoing coronary angiography because of chest pain with hepatitis C virus have a higher prevalence of obstructive coronary artery disease than a control group. Arch Med Sci 2008; 4: 452-4.
14. Kappam H, Aronow WS, Chilappa K, et al. Association of the QRS duration on the resting electrocardiogram with the severity of coronary artery disease in 2,196 patients undergoing coronary angiography for suspected coronary artery disease. Arch Med Sci 2009; 5: 163-5.
15. Shao JH, Aronow WS, Raviglione G, et al. Prevalence of a minimal luminal cross sectional area of coronary arteries < 4 mm² determined by intravascular ultrasound in patients with coronary artery calcium scores of 0-100, 100-200, 200-300, 300-400, and >400 determined by cardiac computer tomography. Arch Med Sci 2009; 5: 172-4.
16. Shen X, Aronow WS, Nair CK, et al. Thoracic aortic atheroma severity predicts high-risk coronary anatomy in patients undergoing transesophageal echocardiography. Arch Med Sci 2011; 7: 61-6.
17. Aronow WS. Osteoporosis, osteopenia, and atherosclerotic vascular disease. Arch Med Sci 2011; 7: 21-6.
18. Duncan KA, Sukhiira R, Aronow WS, et al. Systolic compression of left main coronary artery by left ventricular pseudoaneurysm complicated by critical stenosis. Arch Med Sci 2012 (in press).
19. Lai HM, Aronow WS, Mercando AD, et al. The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. Med Sci Monit 2011; 17: CR683-6.
20. Nicholls SJ, Wolksi K, Sipahi I, et al. Rate of progression of coronary atherosclerotic plaque in women. J Am Coll Cardiol 2007; 49: 1546-51.
21. Zhao XQ, Kosinski AS, Barnhart HX, et al. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery trial. Med Sci Monit 2003; 9: CR48-54.
22. Mancini GB, Hartigan PM, Bates ER, et al. Angiographic disease progression and residual risk of cardiovascular events while on optimal medical therapy. Observations from the COURAGE trial. Circulation: Cardiovasc Interven 2011; 4: 545-52.
23. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society for Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 2011; 57: 2037-114.
24. Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.